Moneycontrol PRO
HomeNewsEma
Jump to
  • Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

    Biocon Biologics gets EMA nod to produce biosimilar Bevacizumab at Bengaluru plant

    This approval will provide significant additional capacity to address patients' needs across markets in Europe, the company said in a statement.

  • Why top Silicon Valley executives are investing in new AI startup Ema

    Why top Silicon Valley executives are investing in new AI startup Ema

    The startup’s captable boasts of former Meta COO Sheryl Sandberg, Yahoo co-founder Jerry Yang among its angels, apart from a slew of institutional investors like Accel, Prosus and Wipro.

  • Former Coinbase CPO’s AI startup Ema raises $25 million from Wipro, Accel and others

    Former Coinbase CPO’s AI startup Ema raises $25 million from Wipro, Accel and others

    Ema also has Yahoo founder Jerry Yang and former Facebook COO Sheryl Sandberg, Ribbit Capital’s Micky Malka among others as angel investors.

  • Covid restrictions: Travelling to the US, or applying for a Green Card? Here's what you need to know

    Covid restrictions: Travelling to the US, or applying for a Green Card? Here's what you need to know

    More travel updates: Up to $3,000 fine for not wearing a mask in the US, Australia may allow fully vaccinated travellers by Christmas, and Italy recognises all versions of AstraZeneca vaccine now.

  • Exclusive | EMA to assess SII’s manufacturing site, says approval for Vaxzevria does not mean nod for Covishield

    Exclusive | EMA to assess SII’s manufacturing site, says approval for Vaxzevria does not mean nod for Covishield

    EMA pointed to a list of six current approved manufacturing sites for Vaxzevria in Belgium, US, UK, Netherlands, South Korea and China – that does not include India.

  • EXPLAINED | What is the exact mechanism for foreign vaccines to get approval in India?

    EXPLAINED | What is the exact mechanism for foreign vaccines to get approval in India?

    The Centre has now announced it will fast-track approval to foreign drug companies whose Covid-19 vaccines have already been approved by the drug certification agencies of the United States, United Kingdom, Japan, European Union and the World Health Organization. But that does not mean the number of steps to vet the vaccine or the requirements for it to be commercially sold has been reduced. We detail the exact process that will determine how long it will take for foreign vaccines to be jabbed in the arms of Indians.

  • EU recommends suspending hundreds of drugs tested by Micro Therapeutic Research Labs

    EU recommends suspending hundreds of drugs tested by Micro Therapeutic Research Labs

    The decision, announced by the European Medicines Agency (EMA) on its website, is the latest blow for India's drug-testing industry, which has run into a series of problems with international regulators in recent year

  • 3 top picks from Reliance Securities: Pidilite, Cipla & IOC

    3 top picks from Reliance Securities: Pidilite, Cipla & IOC

    Following are the top picks from Reliance Securities.

  • To cut healthcare costs, US must partner India: Biocon's Shaw

    To cut healthcare costs, US must partner India: Biocon's Shaw

    Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.

  • Biocon to see inspections by USFDA & EMA in April-May: Sources

    Biocon to see inspections by USFDA & EMA in April-May: Sources

    Biotech company, Biocon will see two crucial inspections later this month and in early April. Company‘s manufacturing sites will come up for inspections by the European medicines agency later this month and next will be an inspection by the US FDA.

  • USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

    USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

    Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

  • Trastuzumab marketing approval may come in 12-18 months: Biocon

    Trastuzumab marketing approval may come in 12-18 months: Biocon

    The European Medicines Agency (EMA) has accepted to review Mylan and Biocon‘s application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.

  • EMA accepts Mylan, Biocon Trastuzumab biosimilar for review

    EMA accepts Mylan, Biocon Trastuzumab biosimilar for review

    This is the second biosimilar submission developed by the partnership that has been accepted for review in Europe, global pharma major Mylan and Biocon said in a statement today.

  • Alkem Labs falls 7% as German regulator accuses of data fudge

    Alkem Labs falls 7% as German regulator accuses of data fudge

    Alkem informed exchanges that the company will be submitting a suitable clarifications to the European Medicines Agency within the stipulated timelines to enable the Committee for Medicinal Products for Human Use (CHMP) take a balanced risk-benefit view with respect to these two products.

  • Alkem Labs accused of fudging trial data by German regulator

    Alkem Labs accused of fudging trial data by German regulator

    The medicines are now being reviewed by the European Medicines Agency (EMA) on the recommendation of the German regulator, which inspected Alkem's Taloja plant in western India last March.

  • EU bans 700 generic drugs for manipulation of trials by GVK

    EU bans 700 generic drugs for manipulation of trials by GVK

    The European Union has banned the marketing of around 700 generic medicines for alleged manipulation of clinical trials conducted by India's pharmaceutical research company GVK Biosciences.

  • World's first malaria vaccine gets nod from EU regulators

    World's first malaria vaccine gets nod from EU regulators

    The world's first malaria vaccine got a green light on Friday from European drugs regulators who recommended it should be licensed for use in babies in Africa at risk of the mosquito-borne disease.

  • German regulator hails EMA's drugs suspension on GVK Bio

    German regulator hails EMA's drugs suspension on GVK Bio

    German drug regulator has welcomed the European Medicine Agency's (EMA) decision to suspend the marketing authorisation of around 700 generic drugs subjected to clinical trials by India's GVK Biosciences.

  • Riverbed Performance Mgmt Solution Recognised As A Value Leader By EMA

    Riverbed Performance Mgmt Solution Recognised As A Value Leader By EMA

    Riverbed Performance Management solutions deliver a unique combination of end-user experience monitoring, transaction tracing, deep component monitoring, and IT infra management.

  • Sell Castorseed, RMSeed on pullback; buy CPO on dip: Geojit

    Sell Castorseed, RMSeed on pullback; buy CPO on dip: Geojit

    Geojit Comtrade has come out with its report on agricultural commodities. The research firm has recommended to sell Castorseed, RMSeed on pullback and buy CPO on dips in its report dated January 17, 2013.

  • Market to correct & then rally around 6100: Anil Manghnani

    Market to correct & then rally around 6100: Anil Manghnani

    In an interview with CNBC-TV18, Anil Manghnani of Modern Shares & Stock Brokers, spoke about his reading of the market and his outlook.

  • Buy Jeera, Turmeric on dip; sell RM Seed on pullback:Geojit

    Buy Jeera, Turmeric on dip; sell RM Seed on pullback:Geojit

    Geojit Comtrade has come out with its report on agricultural commodities. The research firm has recommended to buy Jeera, Turmeric on dip and sell RM Seed on pullback in its report dated December 12, 2012.

  • Sell Wheat below Rs 1510: Geojit Comtrade

    Sell Wheat below Rs 1510: Geojit Comtrade

    Geojit Comtrade has come out with its report on agricultural commodities. The research firm has recommended to sell Castorseed on pullback; Wheat below Rs 1510, Maize below Rs 1475, in its report dated September 04, 2012.

  • Gold has target at USD 1500: India Forex

    Gold has target at USD 1500: India Forex

    India Forex has come out with its technical outlook on Gold and Crude.

  • Buy Nifty future in 4625-4630 range: ICICIdirect.com

    Buy Nifty future in 4625-4630 range: ICICIdirect.com

    ICICIdirect.com has come out with its report on Nifty Future, Tata Motors, HCL Technology, ITC and Hindustan Zinc

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347